Andrew is a corporate partner focusing on equity capital markets, stock market compliance and mergers & acquisitions.
He has been recognised by The Legal500 Asia Pacific as a Recommended Lawyer for Capital Markets in Australia (2025) and has extensive experience in advising corporate clients on public capital markets including initial public offerings (IPOs) for listing on the Australian Securities Exchange (ASX) with over 30 IPOs completed – plus follow on or secondary capital raisings for a large number of listed companies (including placements, rights issues, share purchase plans) together with acting in a number of mergers / takeovers / schemes of arrangement.
Andrew led the largest ASX listing for CY2023 (Freightways Group Limited – which is now dual listed on the New Zealand Exchange and ASX) and the second largest ASX listing for CY2024 (Symal Group Limited). Andrew's dual listing of Avita Medical Group Ltd was awarded the Australian Investment Council Investment Capital award for Private Equity Transaction of the Year 2020.
He also advises on private equity transactions for unlisted companies (including mergers and acquisitions, private capital raisings, private equity or venture and seed capital, other hybrid security arrangements and shareholder agreements), as well as compliance and regulatory issues under the Australian Corporations Act.
He has a practical knowledge of international and local considerations in international cross border transactions having also practiced law in London for a number of years. In his practice Andrew advises many clients in the technology and life sciences sectors including start up and established fintech, software technology and biotechnology companies.
Andrew's qualifications as an accountant complement his depth of experience in a wide range of large commercial transactions for private equity investors and also in the public equity markets. This allows him to work closely with equity capital markets clients and help shape their strategic plans for growth and success.
